For more information, please visit: www.ignyta.com.
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that Ignyta management will host a conference call and live webcast on December 1, 2016, at 2:00 p.m. CET (8:00 a.m. ET) to provide highlights related to six presentations at the 2016 EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium. In particular, the conference call will cover a substantial Phase 1b clinical data update of RXDX-105—Ignyta's VEGFR-sparing, potent RET inhibitor—and the first disclosed preclinical data of RXDX-106—Ignyta's TYRO3, AXL and MER (or TAM) and c-MET inhibitor. A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/investors/, and will be archived and available at that site for 14 days. Alternatively, callers may participate in the conference call by dialing 888-727-7630 (domestic) or 913-312-1448 (international), and entering passcode 8940588. About Ignyta, Inc. Blazing a New Future for Patients with Cancer ™ At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class and best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.